Company
East Melbourne, VIC
Every investor coverage indicates participated in a round Centre for Eye Research Australia raised.
Companies Centre for Eye Research Australia acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Nathan Kerr | Principal Investigator | Brandon Capital portfolio |
| Penny Allen | Associate Professor | @AuManufacturing |
| Professor Keith Martin | Managing Director (former) | cera.org.au, Breakthrough Victoria |
Stories naming Centre for Eye Research Australia. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Mirugen, a Melbourne biotech spun out of an eye research institute, has closed a A$4.5m seed round with three backers and hired Charlotte Casebourne Stock as chair and acting chief executive.
Also cera.org.au·Brandon BioCatalyst portfolio·insightnews.com.au
Breakthrough Victoria marks the opening of an eye research facility it backed with $10 million; the CERA-affiliated centre expects to treat thousands of patients and create dozens of jobs.
Melbourne AI eye-screening firm Eyetelligence secured US$12 million from Ascertain, the New York healthcare investor's first international deal, and will relaunch in the US under the Optain brand.
PolyActiva finished enrolling patients in its Phase I glaucoma implant trial and closed a AU$10 million raise from existing backers including the MRCF and Yuuwa Capital to fund further clinical studies.
Okogen has begun Australian Phase II trials of its conjunctivitis therapy OKG-0301 across multiple sites, with Brandon Capital's MRCF having invested in the biotech's Series A in December 2017.